Therapeutic implication of CD38 in CLL
Description: Project Narrative CD38 is a multifunctional ecto-enyzme / co-receptor, which is primarily expressed on the surface of B and T-lymphocytes and in chronic lymphocytic leukemia (CLL) patients, its increased expression on the B-CLL lymphocytes is associated with an aggressive disease course and poor prognosis. How CD38 is preferentially utilized by the CLL cells and the tumor- supportive T-cells in their microenvironment and whether targeted disruption of CD38 in CLL patients will yield clinical benefit remains unknown. This grant application (and through use of primary samples on an accompanying Phase II clinical trial) will investigate the biological properties of CD38 in CLL and T-cells that cooperatively drive disease progression and how targeted inhibition of CD38 in patients with an anti-CD38 monoclonal antibody can potentially restore anti-tumor T-cell immunity and provide increased clinical benefit to patients suffering from CLL.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2019-09-04
End date: 2025-08-31
Investigator: EDUARDO N CHINI
Institution: MAYO CLINIC JACKSONVILLE
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 43
Funder award ID: R01CA233790
OpenAlex ID: G7576152829